EverythingALS
EverythingALS is a Seattle-based 501(c)(3) nonprofit that uses AI and an open-data platform to connect ALS patients, caregivers, researchers, and drug companies across 44 countries, offering clinical trial matching (SAVA AI), speech and motor assessment apps, and research data infrastructure.
- Company typePrivate
- Founded2020
- HeadquartersSeattle, United States
- Headcount11–50
- GTM typeB2C
- OfferingSoftware
What EverythingALS does
EverythingALS is a patient-focused nonprofit 501(c)(3) organization, operating as a brand of the Peter Cohen Foundation, that applies AI and data science to ALS across the care-to-cure continuum. Founded in 2020 and headquartered in Seattle with 11-50 employees, the organization serves people with ALS (pALS), caregivers (cALS), academic researchers, and biopharmaceutical companies through an open-data platform whose community spans 44 countries. Core offerings include SAVA AI (AI-powered clinical trial matching with reported 92% accuracy), the EverythingALS Mobile App, the ALS Motor App (self-administered assessment of 46 motor tasks), the ECAS Copilot (AI-assisted cognitive screening with live transcription), and NeuroLens (digital diagnostic for early detection in pre-symptomatic gene carriers, in development with Massachusetts General Hospital).
The technical stack combines speech analysis (OpenSMILE-based acoustic features; up to 90% AUC for ALS stage distinction), computer vision for facial metrics, NLP (Whisper OpenAI transcription, Bing query analysis at AUC 0.81), and multi-omics machine learning. These capabilities were developed in collaboration with MIT, MGH, UT Austin, Google, Gladstone Institute, and AnswerALS. Revenue comes exclusively from tax-deductible donations and research grants (~$1.4M disclosed to date, including a $400K grant in August 2023 and a $1M co-investment in the Allen Institute's Brain Health Accelerator in June 2026); all patient-facing products are free. Go-to-market is community-led and event-driven, executed through bi-monthly virtual Expert Talks, Citizen Research sessions, Fireside Chats, a Pathfinders advocate program, and a multi-channel social presence.
EverythingALS firmographics
Firmographics- Name
- EverythingALS
- Legal name
- Peter Cohen Foundation
- Website
- https://everythingals.org
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- EverythingALS is a Seattle-based 501(c)(3) nonprofit that uses AI and an open-data platform to connect ALS patients, caregivers, researchers, and drug companies across 44 countries, offering clinical trial matching (SAVA AI), speech and motor assessment apps, and research data infrastructure.
- Ownership category
- akta.pro rank
EverythingALS industry classification
Industry- Product category
- Digital Health Research Platform
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Computer Systems Design and Related Services (54151)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Services-Computer Programming, Data Processing, Etc. (7370)
- akta.pro primary industry
- Data Aggregation, Interoperability & APIs for RPM (FHIR/IoMT Gateways) (HLACAFAO)
- akta.pro secondary industry
- Home Diagnostics & At-Home Testing Connectivity Platforms (HLACAFAK)
Keywords
Where EverythingALS is headquartered
LocationHeadquarters
- HQ city
- Seattle
- HQ country
- United States
- HQ region
- North America
Markets served
EverythingALS business model
Business model- GTM type
- B2C
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Donations and Charitable Contributions: EverythingALS is a brand of Peter Cohen Foundation, a non-profit 501(c)(3) organization (EIN 84-3055901). 100% of donations are applied to help people with ALS directly with their expenses and ALS research. Donations are tax-deductible.
- Grant Funding: The organization receives grant funding for specific research projects, such as the $400,000 grant from businesswire for NeuroLens development with Massachusetts General Hospital.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | Monthly | Free access to SAVA AI clinical trial matching platform |
| Freemium | Monthly | Free mobile app access |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels9 records
EverythingALS product offering
Product offeringCore offering
EverythingALS is a patient-focused nonprofit that provides a suite of digital health tools and an open-data platform for ALS care, research, and clinical trial engagement. Core offerings include the SAVA AI clinical trial matching tool, the EverythingALS mobile application, the ALS Motor App for remote motor assessment, the ECAS Copilot for AI-assisted cognitive screening, the Open Data Platform for research collaboration, and the in-development NeuroLens digital diagnostic tool.
Product overview
EverythingALS is a patient-focused nonprofit offering a platform of digital health tools and open-data resources for ALS care and research. The core portfolio includes the EverythingALS Mobile App and Open Data Platform for patient engagement and data sharing; SAVA AI for AI-powered clinical trial matching; the ALS Motor App for remote motor assessment; the ECAS Copilot for AI-assisted cognitive screening; and NeuroLens (in development) as a digital diagnostic tool for early detection. The organization also hosts Expert Talks and community events. The platform processes speech, video, and structured clinical data using machine learning and NLP to support early detection, disease monitoring, and clinical trial recruitment.
Differentiator
Problem solved
Functional benefit
Brands
- SAVA AI: AI-powered online tool that matches amyotrophic lateral sclerosis (ALS) patients with clinical trials by analyzing their health data against eligibility requirements, achieving 92% accuracy rate.
- NeuroLens
Products and services
- SAVA AI AI-powered online tool that matches ALS patients with clinical trials by analyzing their health data against eligibility requirements. Reports a 92% accuracy rate in identifying relevant studies and can connect patients to suitable trials in seconds. Free for ALS patients.
- EverythingALS Mobile App
Quantifiable outcome
- 92% accuracy rate in identifying relevant clinical trials
- +2 more outcomes
Companies that use EverythingALS
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles4 records
EverythingALS technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability10 records
Feature5 records
EverythingALS partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered minor and core.
- NeuroSense TherapeuticsminorEverythingALS hosted a virtual community event on June 24, 2026 to discuss emerging clinical data on PrimeC, NeuroSense's investigational ALS treatment. Prof. Jeffrey Rosenfeld from Loma Linda University and NeuroSense CEO Alon Ben-Noon led the discussion focused on ALS patients, families, caregivers, and clinicians.
- Vision 2030coreEverythingALS and Vision 2030 announced a $1M initial investment in the Allen Institute's newly launched Brain Health Accelerator to accelerate ALS research. The ALS Network and The Head Cook for ALS also made additional contributions, with amounts multiplied up to 5:1 by the Allen Institute's infrastructural and ALS-related allocations.
- Allen InstitutecoreAllen Institute launched the Brain Health Accelerator with $400 million in funding aimed at developing gene therapies for neurodegenerative diseases including ALS. EverythingALS and Vision 2030 invested $1M initial investment in this initiative, with ALS as the first disease studied under the accelerator.
- Massachusetts General HospitalcoreEverythingALS.org and Massachusetts General Hospital received a $400,000 grant to develop NeuroLens, a digital diagnostic tool for early detection of ALS. The project involves digital monitoring of pre-symptomatic gene carriers to identify early signs of ALS and improve diagnosis speed.
- MITcoreCollaboration with MIT on speech analysis development using audio and facial metrics for early detection, clinical endpoints, and better voice recognition tools for ALS.
- UT AustincoreCollaboration with UT Austin on speech analysis development using audio and facial metrics for early detection, clinical endpoints, and better voice recognition tools for ALS.
- GooglecoreCollaboration with Google on speech analysis development using audio and facial metrics for early detection, clinical endpoints, and better voice recognition tools for ALS.
- Gladstone InstitutecoreSupporting Gladstone Institute with multi-omics analysis with machine learning and big data to uncover ALS causes, subtypes, pathways, and drug targets.
- AnswerALScoreSupporting AnswerALS with multi-omics analysis with machine learning and big data to uncover ALS causes, subtypes, pathways, and drug targets.
- VectorY TherapeuticsminorCollaboration with VectorY Therapeutics as part of historic ALS investment momentum, with VectorY dosing first patient in its ALS trial.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
EverythingALS competitors and assessment
Company assessmentDirect peers
- ALS Therapy Development Institute (ALS TDI): Patient-focused nonprofit conducting ALS research with its own lab and data programs. Directly comparable as an ALS-focused nonprofit investing in technology and data science to accelerate cures.
- Answer ALS: Multi-institution ALS research program that EverythingALS already supports. Comparable as an ALS data and research platform aggregating patient data and biosamples for scientific collaboration.
- ALS Finding a Cure: Nonprofit led by former chairman of The ALS Association that co-led EverythingALS's $400K NeuroLens grant. Comparable as an ALS-focused research funder and grant-maker supporting clinical and translational projects.
- Project ALS: Patient-driven nonprofit funding ALS research at leading institutions. Comparable in mission and operating model (small nonprofit funding ALS research with patient focus) though less technology-led.
- Healey Center for ALS at Massachusetts General Hospital: Major academic ALS clinical and research center where EverythingALS has co-developed NeuroLens. Comparable in driving ALS platform trials, biomarker development, and clinical trial recruitment.
- I AM ALS: Patient-led ALS advocacy nonprofit focused on community organizing, policy, and research funding. Comparable as a grassroots, patient-driven ALS nonprofit, though less focused on AI and digital biomarkers.
Broad incumbents
- The ALS Association: Largest US ALS nonprofit providing care services, advocacy, and research funding. Overlaps with EverythingALS on patient support, clinical trial awareness, and research funding, but operates at far greater scale with a broader portfolio.
- Muscular Dystrophy Association (MDA): Large nonprofit covering ALS along with dozens of neuromuscular diseases. Comparable in patient services and research funding, but with a much broader disease portfolio and deeper institutional resources.
Others
- NEALS Consortium: Network of ALS clinical trial sites collaborating on trial design and execution. Comparable as an ecosystem partner that EverythingALS could feed patients into via SAVA AI matching.
- Biogen: Biopharmaceutical company with a marketed ALS therapy (Qalsody). Thematically comparable as a major pharma player whose clinical trial recruitment needs EverythingALS's SAVA AI platform is positioned to address.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
EverythingALS social profiles
Digital presenceEverythingALS financial estimates
Financial estimateRevenue estimate
Valuation estimate
EverythingALS leadership team
Management profileNumber of profiles
Profiles2 records
EverythingALS funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
EverythingALS M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about EverythingALS
What does EverythingALS do?
EverythingALS is a patient-focused nonprofit that provides a suite of digital health tools and an open-data platform for ALS care, research, and clinical trial engagement. Core offerings include the SAVA AI clinical trial matching tool, the EverythingALS mobile application, the ALS Motor App for remote motor assessment, the ECAS Copilot for AI-assisted cognitive screening, the Open Data Platform for research collaboration, and the in-development NeuroLens digital diagnostic tool.
Is EverythingALS a public or private company?
EverythingALS is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was EverythingALS founded?
EverythingALS was founded in 2020. It employs 11 to 50 people.
Where is EverythingALS based?
EverythingALS is headquartered in Seattle, United States, in the North America region.
How does EverythingALS make money?
Two revenue lines are on record. Donations and Charitable Contributions are the primary driver. The others are grant Funding.
Who are EverythingALS's main competitors?
Direct peers on record are ALS Therapy Development Institute (ALS TDI), Answer ALS, ALS Finding a Cure, Project ALS, Healey Center for ALS at Massachusetts General Hospital and I AM ALS. Broad incumbents are The ALS Association and Muscular Dystrophy Association (MDA). Others are NEALS Consortium and Biogen.
Does EverythingALS have an API?
No public API is recorded for EverythingALS.
What industry is EverythingALS in?
EverythingALS's product category is Digital Health Research Platform. Its primary akta.pro industry code is HLACAFAO, Data Aggregation, Interoperability & APIs for RPM (FHIR/IoMT Gateways), with a secondary code of HLACAFAK, Home Diagnostics & At-Home Testing Connectivity Platforms. Its NAICS code is 334510 and its SIC code is 3841.